Therefore, the mechanism for activation of CTLs specific for tumor cells might not be the same in the case of an anti-CCR8 antibody for depletion of local Tregs and the case of a DHP column for depletion of blood LAP+ T cells, for example priming of CTLs in the secondary lymphoid organs. The gene discussed is CCR8; the disease is neoplasm.